| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $45,643,381 ) (Continued on the next page) |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA258751 | Combating melanoma resistance by targeting ABL1/2 | 000 | 3 | NIH | 4/3/2024 | $553,135 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01MD016864 | K-VAC: Kentucky Vaccinating Appalachian Communities | 000 | 3 | NIH | 3/4/2024 | $563,667 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K22CA258678 | Admixture mapping of mosaic copy number alterations for identification of cancer drivers | 000 | 3 | NIH | 3/11/2024 | $181,348 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA054347 | Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Opioid Abuse Potential and Opioid Safety | 001 | 3 | NIH | 4/24/2024 | $69,574 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA054347 | Cannabis Modulation of Outcomes Related to Opioid Use Disorder: Opioid Withdrawal, Opioid Abuse Potential and Opioid Safety | 000 | 3 | NIH | 1/31/2024 | $626,186 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01ES033767 | Phthalate-Induced Dysregulation of Prostaglandin and Angiogenic Function During Ovulation in Women | 000 | 3 | NIH | 10/23/2023 | $439,396 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01DK128022 | Elucidating Molecular Mechanisms Linking Fructose to Cholesterol Metabolism | 000 | 3 | NIH | 1/4/2024 | $100,543 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K23DK128562 | Classical and Alternative Renin-Angiotensin System Dysregulation in Sepsis-Associated AKI: A Reverse Translation Approach | 001 | 3 | NIH | 3/11/2024 | $0 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K23DK128562 | Classical and Alternative Renin-Angiotensin System Dysregulation in Sepsis-Associated AKI: A Reverse Translation Approach | 000 | 3 | NIH | 11/21/2023 | $157,563 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01DK128022 | Elucidating Molecular Mechanisms Linking Fructose to Cholesterol Metabolism | 001 | 3 | NIH | 1/31/2024 | $47,643 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DK128033 | Mirabegron and tadalafil effectiveness for treatment of prediabetes | 000 | 3 | NIH | 12/15/2023 | $275,400 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K23MH126211 | A Precision Medicine Approach to Target Engagement for Emotion Regulation | 000 | 3 | NIH | 1/19/2024 | $165,745 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00HL145117 | Macrophage Pyroptosis in Abdominal Aortic Aneurysm | 000 | 5 | NIH | 11/14/2023 | $249,000 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R34DA060087 | Optimizing Low Threshold TelePrEP Care in Syringe Service Programs for People who Inject Drugs in Appalachia | 000 | 1 | NIH | 4/22/2024 | $194,380 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL163589 | Targeting Endothelial Cell Mineralocorticoid Receptor Against Aortic Aneurysm in Females | 000 | 1 | NIH | 3/8/2024 | $649,718 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01HL168085 | Development of a Percutaneous Double Lumen Cannula-Based Cavopulmonary Assist System Toward Clinical Application | 000 | 1 | NIH | 1/31/2024 | $663,863 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21ES036036 | R21-UKY East Palestine Train Derailment Health Tracking Study | 000 | 1 | NIH | 1/22/2024 | $221,953 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21DA060354 | Regulation of cocaine use by astrocyte voltage-gated channels | 000 | 1 | NIH | 3/21/2024 | $183,859 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS136272 | Harnessing engineered drug-free polymeric nanoformulations to reprogram innate immune cells for spinal trauma | 000 | 1 | NIH | 3/20/2024 | $326,594 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00AR081367 | Contribution of ribosome specialization to the pathophysiology of muscular dystrophy | 000 | 3 | NIH | 1/11/2024 | $249,000 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00DA056288 | Neurocognitive Impairments Resulting from Adolescent Prescription Opioid Use Disorder: Longitudinal Impact, Neural Mechanisms, and Comorbidities | 000 | 3 | NIH | 3/20/2024 | $249,000 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21NS137256 | Combinatorial approach to restore breathing after spinal cord injury | 000 | 1 | NIH | 3/19/2024 | $222,109 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AG083820 | Deciphering genetics of PLCG2 alternative splicing to understand AD risk | 000 | 1 | NIH | 4/15/2024 | $415,626 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AI180274 | Molecular mechanisms of Helicobacter pylori trans-kingdom DNA conjugation | 000 | 1 | NIH | 11/22/2023 | $192,814 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS119165 | Translational Approaches to Mitigate Enhanced Alzheimer?s Disease Risk Following a Mild TBI | 000 | 2 | NIH | 4/16/2024 | $382,500 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA278989 | Mechanistic and structural insights into a new pro-metastatic collagen glucosyltransferase | 001 | 1 | NIH | 1/22/2024 | $0 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA278989 | Mechanistic and structural insights into a new pro-metastatic collagen glucosyltransferase | 000 | 1 | NIH | 1/16/2024 | $593,786 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01CA282254 | Integrative Targeted Therapy for Melanoma | 000 | 1 | NIH | 3/22/2024 | $632,195 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | F32AR083259 | A multispecies system for elucidating proliferative control mechanisms during mammalian skin and musculoskeletal regeneration | 000 | 1 | NIH | 4/15/2024 | $74,292 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG084670 | Emerging role of PAD4 mediated TDP-43 citrullination in the neuropathology of LATE and Alzheimer?s Disease Related Dementias | 000 | 1 | NIH | 2/7/2024 | $690,893 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00CA249048 | A pro-metastatic secretory program activated by epithelial-to-mesenchymal transition | 001 | 3 | NIH | 4/23/2024 | $18,022 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R00CA249048 | A pro-metastatic secretory program activated by epithelial-to-mesenchymal transition | 000 | 3 | NIH | 3/12/2024 | $224,101 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21NS135089 | Cannabidiol (CBD) as a Potential Therapeutic for Experimental Subarachnoid Hemorrhage | 000 | 1 | NIH | 12/5/2023 | $229,500 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | G08LM014412 | DASH-ing to Heart Health: Supporting Low-Income African American Women with an Interactive "Meals that Heal" Resource Book | 000 | 1 | NIH | 12/20/2023 | $118,770 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01AG070952 | Dynamic GABA and Glutamate Neurotransmission in Alzheimer?s Disease and Aging | 000 | 2 | NIH | 1/29/2024 | $596,810 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS127974 | Predictors and Biomarkers for VCID versus Cognitive Recovery after Stroke Thrombectomy in Rural Appalachia | 001 | 2 | NIH | 4/11/2024 | $36,237 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS127974 | Predictors and Biomarkers for VCID versus Cognitive Recovery after Stroke Thrombectomy in Rural Appalachia | 001 | 2 | NIH | 4/11/2024 | $12,056 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS127974 | Predictors and Biomarkers for VCID versus Cognitive Recovery after Stroke Thrombectomy in Rural Appalachia | 000 | 2 | NIH | 3/11/2024 | $512,407 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01NS127974 | Predictors and Biomarkers for VCID versus Cognitive Recovery after Stroke Thrombectomy in Rural Appalachia | 000 | 2 | NIH | 3/11/2024 | $108,515 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21NS128749 | Development of a Novel Animal Model for Spinal Cord Injury with Sepsis | 000 | 2 | NIH | 4/3/2024 | $190,837 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21AI178652 | Genetic screen to define the regulation of beta-hemolysin toxin expression in Streptococcus agalactiae | 000 | 2 | NIH | 4/16/2024 | $229,500 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01DA058933 | Neurobehavioral mechanisms underlying xylazine and fentanyl co-use and withdrawal | 000 | 2 | NIH | 4/23/2024 | $502,057 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R33DC019602 | Hearing Healthcare Assessment in Rural Communities (HHARC) | 001 | 3 | NIH | 10/27/2023 | $29,645 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R21ES035320 | Impact of Landfill Mitigation Efforts to Reduce Air Toxics in Bristol, Tennessee and Virginia | 000 | 2 | NIH | 4/2/2024 | $191,846 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R01GM150200 | Study of PTPRF-Mediated Regulation of Wnt Signaling | 000 | 2 | NIH | 2/27/2024 | $312,413 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | K01AG070279 | Cognitive Aging Trajectories in Survivors of Trauma | 000 | 2 | NIH | 1/17/2024 | $125,795 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | P20GM148326 | Center of Biomedical Research Excellence in CNS Metabolism | 000 | 2 | NIH | 4/22/2024 | $1,917,850 |
| 2024 | 2024 | University of Kentucky Research Foundation, The | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R13OH012359 | SouthON Conference Grant | 01 | 3 | CDC | 2/5/2024 | $0 |
| 2024 | 2024 | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE | 500 S LIMESTONE | LEXINGTON | KY | 40526-0001 | FAYETTE | USA | R13OH012359 | SouthON Conference Grant | 00 | 3 | CDC | 12/1/2023 | $20,000 |
|